.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,642,079

« Back to Dashboard

Claims for Patent: 8,642,079

Title:Solid formulations of ospemifene
Abstract: This invention relates to a solid drug formulation comprising granulates containing a therapeutically active compound of the formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, in combination with one or more intra-granular excipients.
Inventor(s): Lehtola; Veli-Matti (Turku, FI), Halonen; Kaija (Rusko, FI)
Assignee: Hormos Medical Corporation (Turku, FI)
Application Number:10/783,024
Patent Claims: 1. A solid drug formulation comprising granulates containing 30 to 90 mg of ospemifene or a pharmaceutically acceptable salt thereof, in combination with one or more intra-granular excipients selected from a disintegrant, a diluent, a binder, and combinations of the same; wherein 90% of the ospemifene or the pharmaceutically acceptable salt thereof has a particle size less than 50 micrometers and 50% of the ospemifene or the pharmaceutically acceptable salt thereof has a particle size less than 15 micrometers.

2. The drug formulation according to claim 1 wherein the active ingredient is ospemifene.

3. The drug formulation according to claim 1 wherein the disintegrant is selected from the group consisting of povidone, crospovidone, carboxymethyl-cellulose, methylcellulose, alginic acid, croscarmellose sodium, sodium starch glycolate, starch, formaldehyde-casein and combinations thereof.

4. The drug formulation according to claim 1 wherein at least one intra-granular excipient is a diluent.

5. The drug formulation according to claim 1 wherein at least one intra-granular excipient is a binder.

6. The drug formulation according to claim 1 wherein the intra-granular excipient is selected from: a combination of at least one diluent and at least one disintegrant; a combination of at least one disintegrant and at least one binder; or a combination of at least one diluent, at least one disintegrant and at least one binder.

7. The drug formulation according to claim 4 wherein the diluent is selected from the group consisting of maltose, maltodextrin, lactose, fructose, dextrin, microcrystalline cellulose, pregelatinized starch, sorbitol, sucrose, silicified microcrystalline cellulose, powdered cellulose, dextrates, mannitol, calcium phosphate and combinations thereof.

8. The drug formulation according to claim 5 wherein the binder is selected from a group consisting of acacia, dextrin, starch, povidone, carboxymethylcellulose, guar gum, glucose, hydroxypropyl methylcellulose, methylcellulose, polymethacrylates, maltodextrin, hydroxyethyl cellulose and combinations thereof.

9. The drug formulation according to claim 1 wherein the granulates are made by wet granulation.

10. The drug formulation according to claim 2 wherein the disintegrant is selected from the group consisting of povidone, crospovidone, carboxymethyl-cellulose, methylcellulose, alginic acid, croscarmellose sodium, sodium starch glycolate, starch, formaldehyde-casein and combinations thereof.

11. The drug formulation according to claim 2 wherein the intra-granular excipient is selected from: a combination at least one diluent and at least one disintegrant; a combination of at least one disintegrant and at least one binder; or a combination of at least one diluent, at least one disintegrant and at least one binder.

12. The drug formulation according to claim 11 wherein the diluent is selected from the group consisting of maltose, maltodextrin, lactose, fructose, dextrin, microcrystalline cellulose, pregelatinized starch, sorbitol, sucrose, silicified microcrystalline cellulose, powdered cellulose, dextrates, mannitol, calcium phosphate and combinations thereof.

13. The drug formulation according to claim 12 wherein the binder is selected from a group consisting of acacia, dextrin, starch, povidone, carboxymethylcellulose, guar gum, glucose, hydroxypropyl methylcellulose, methylcellulose, polymethacrylates, maltodextrin, hydroxyethyl cellulose and combinations thereof.

14. A solid drug formulation comprising granulates containing 30 to 90 mg of ospemifene or a pharmaceutically acceptable salt thereof in combination with one or more intra-granular excipients selected from pregelatinized starch, maize starch, povidone, sodium starch glycolate, and magnesium stearate, wherein at least 80% of the formulation is dissolved within 30 minutes after subjecting said formulation to dissolution testing at pH 9.8 according to the USP 24 paddle method; wherein 90% of the ospemifene or the pharmaceutically acceptable salt thereof has a particle size less than 50 micrometers and 50% of the ospemifene or the pharmaceutically acceptable salt thereof has a particle size less than 15 micrometers.

15. The drug formulation according to claim 1 wherein the disintegrant is sodium starch glycolate.

16. The drug formulation according to claim 2 wherein the disintegrant is sodium starch glycolate.

17. The drug formulation according to claim 1 wherein the disintegrant is in the range of 0.1 to 10 weight % of the granulates and wherein at least 80% of the formulation is dissolved within 30 minutes after subjecting said formulation to dissolution testing at pH 9.8 according to the USP 24 paddle method.

18. The drug formulation according to claim 6, wherein the at least one diluent comprises pregelatinized starch, the at least one disintegrant comprises sodium starch glycolate, and the at least one binder comprises povidone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc